Author | Little Fish Periodically, major pharmaceutical media and authoritative journals summarize the development of ADCs. Recently, a review on ADCs published by the internationally renowned journal ACS caught our attention. As a member of CAS (American Chemical Society), Janet M. Sasso’s team innovatively used patents and articles related to ADCs within CAS as data … Read more
Representative ADC Technology Platforms As a combination drug, any component of an ADC can be replaced or modified.Therefore, the ADC combination technology platform has significant extensibility, allowing for the iterative combination of a rich variety of products.The development history of internationally leading ADC companies is rooted in having a competitive platform.Table 1 lists several representative … Read more
Known as magic bullets, ADCs have been highly praised in recent years. The design concept of these drugs is clear: to utilize the high specificity of antigen-antibody binding to selectively deliver toxins to antigen-positive cells, thereby selectively killing target cells and reducing damage to normal cells. However, like other drugs, the actual performance of ADCs … Read more
Introduction Antibody-Drug Conjugates (ADCs) are targeted therapies that consist of antibodies, linkers, and cytotoxic drugs, using monoclonal antibodies as carriers to efficiently deliver cytotoxic drugs to target tumor cells in a targeted manner, combining the powerful killing effect of traditional chemotherapy with the tumor-targeting capability of antibody drugs. An ideal ADC maintains stability in the … Read more
Source: Xiaoyao Shuo Yao Introduction Antibody-drug conjugates (ADC) are a powerful cancer treatment method that combines monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs linked by a linker. ADCs utilize the specificity of antibodies for their target antigens, combined with the potency of cytotoxic drugs, to selectively kill tumor cells expressing the target … Read more
What Is ADC? Antibody-drug conjugates (ADC) are a new type of targeted therapeutic drug, composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers. They combine the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. This structure allowsADC to deliver drugs directly … Read more
Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more